Charlotte's Web (CWBHF) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	000-56364
Entity Registrant Name	Charlotte's Web Holdings, Inc.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1508633
Entity Address, Address Line One	700 Tech Court
Entity Address, City or Town	Louisville
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80027
City Area Code	720
Local Phone Number	484-8930
Title of 12(g) Security	Common stock, no par value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		152,441,782
Amendment Flag	false
Entity Central Index Key	0001750155
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 60,781	$ 66,963
Accounts receivable, net	2,578	1,847
Inventories, net	25,573	26,953
Employee retention credit receivable	4,261	0
Prepaid expenses and other current assets	7,944	7,998
Total current assets	101,137	103,761
Property and equipment, net	27,962	29,330
License and media rights	25,041	26,871
Operating lease right-of-use assets, net	16,025	16,519
SBH purchase option and other derivative assets	2,715	3,620
Intangible assets, net	1,559	1,771
Other long-term assets	1,532	5,770
Total assets	175,971	187,642
Current liabilities:
Accounts payable	3,707	4,018
License and media rights payable - current	10,510	7,759
Accrued and other current liabilities	6,138	7,344
Lease obligations – current	2,268	2,306
Total current liabilities	22,623	21,427
Convertible debenture	38,426	37,421
Lease obligations – noncurrent	17,364	17,905
License and media rights payable - noncurrent	15,921	20,383
Derivative and other long-term liabilities	6,738	13,001
Total liabilities	101,072	110,137
Commitments and contingencies (note 7)
Shareholders’ equity:
Common shares, nil par value; unlimited shares authorized as of March 31, 2023 and December 31, 2022, respectively; 152,432,914 and 152,135,026 shares issued and outstanding as of March 31, 2023 and December 31, 2022	1	1
Additional paid-in capital	325,737	325,431
Accumulated deficit	(250,839)	(247,927)
Total shareholders’ equity	74,899	77,505
Total liabilities and shareholders’ equity	$ 175,971	$ 187,642

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common shares, issued (in shares)	152,432,914	152,135,026
Common shares, outstanding (in shares)	152,432,914	152,135,026

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 17,010	$ 19,356
Cost of goods sold	7,093	7,643
Gross profit	9,917	11,713
Selling, general, and administrative expenses	17,513	20,355
Operating loss	(7,596)	(8,642)
Other (expense) income, net	(698)	(84)
Change in fair value of financial instruments and other	5,382	100
Loss before provision for income taxes	(2,912)	(8,626)
Income tax expense	0	0
Net loss	$ (2,912)	$ (8,626)
Net loss per common share, basic (in usd per share)	$ (0.02)	$ (0.06)
Net loss per common share, diluted (in usd per share)	$ (0.02)	$ (0.06)
Weighted-average shares used in computing net loss per share, basic (in shares)	152,314,150	144,990,224
Weighted-average shares used in computing net loss per share, diluted (in shares)	152,314,150	144,990,224

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Restricted share units	Common Shares	Common Shares Restricted share units	Additional Paid-in Capital	Additional Paid-in Capital Restricted share units	Accumulated Deficit
Balance (in shares) at Dec. 31, 2021			144,659,964
Balance at Dec. 31, 2021	$ 130,446		$ 1		$ 319,059		$ (188,614)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of witholding (in shares)				77,193
Common shares issued upon vesting of restricted share units, net of withholding		$ (45)				$ (45)
Harmony hemp contingent equity compensation (in shares)			169,045
Harmony Hemp contingent equity compensation	165				165
ATM program issuance costs (in shares)			239,500
ATM program issuance costs	(2)				(2)
Share-based compensation	1,214				1,214
Net loss	(8,626)						(8,626)
Balance (in shares) at Mar. 31, 2022			145,145,702
Balance at Mar. 31, 2022	123,152		$ 1		320,391		(197,240)
Balance (in shares) at Dec. 31, 2022			152,135,026
Balance at Dec. 31, 2022	77,505		$ 1		325,431		(247,927)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of witholding (in shares)				297,888
Common shares issued upon vesting of restricted share units, net of withholding		$ (69)				$ (69)
Share-based compensation	375				375
Net loss	(2,912)						(2,912)
Balance (in shares) at Mar. 31, 2023			152,432,914
Balance at Mar. 31, 2023	$ 74,899		$ 1		$ 325,737		$ (250,839)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,912)	$ (8,626)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,792	2,078
Change in fair value of financial instruments	(5,351)	(100)
Convertible debenture interest	697	0
Changes in right-of-use assets	493	636
Share-based compensation	375	1,379
Allowance for credit losses	326	0
Other	442	84
Changes in operating assets and liabilities:
Accounts receivable, net	(1,212)	2,228
Inventories, net	1,187	(979)
Prepaid expenses and other current assets	480	1,313
License and media rights	(2,000)	0
Operating lease obligations	(925)	(644)
Accounts payable, accrued and other liabilities	(1,098)	(2,797)
Other operating assets and liabilities, net	(367)	749
Net cash used in operating activities	(6,073)	(4,679)
Cash flows from investing activities:
Other investing activities	(40)	(271)
Net cash used in investing activities	(40)	(271)
Cash flows from financing activities:
Other financing activities	(69)	(47)
Net cash used in financing activities	(69)	(47)
Net decrease in cash and cash equivalents	(6,182)	(4,997)
Cash and cash equivalents —beginning of period	66,963	19,494
Cash and cash equivalents —end of period	60,781	14,497
Non-cash activities:
Non-cash purchases of property and equipment	$ 0	$ (67)

DESCRIPTION OF BUSINESS AND PRE

DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS	DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS Description of the Business Charlotte’s Web Holdings, Inc. together with its subsidiaries (collectively "Charlotte's Web" or the “Company”) is a public company incorporated pursuant to the laws of the Province of British Columbia and a Certified B Corp. The Company’s common shares are publicly listed on the Toronto Stock Exchange (“TSX”) under the symbol “CWEB” and quoted on the OTCQX under the symbol "CWBHF." The Company’s corporate headquarters is located in Louisville, Colorado in the United States of America. The majority of the Company's business is conducted in the United States of America. The Company’s primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids and other hemp compounds. Hemp extracts are produced from the plant Cannabis sativa L. (“Cannabis”), and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol ("THC") concentration of not more than 0.3% on a dry weight basis ("Hemp"). The Company is engaged in research involving the effectiveness of a broad variety of compounds derived from Hemp. The Company’s current product categories include human ingestible products: tinctures (liquid product), capsules, gummies, topicals, and pet products. The Company’s products are distributed through its e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers. The Company does not currently produce or sell medicinal or recreational marijuana or products derived from high THC Cannabis plants. On March 2, 2021, Charlotte’s Web executed an Option Purchase Agreement pursuant to which the Company has the option to acquire Stanley Brothers USA Holdings, Inc. (“Stanley Brothers USA”), a Cannabis wellness incubator. Until the Stanley Brothers USA Holdings Purchase Option ("SBH Purchase Option") is exercised, both Charlotte’s Web and Stanley Brothers USA will continue to operate as standalone entities in the US. Internationally, the companies are able to explore opportunities where Cannabis is federally permissible. The Company does not currently have any plans to expand into high-THC products in the near future. The Company grows its proprietary hemp domestically in the United States on farms leased in northeastern Colorado and sources hemp through contract farming operations in Arizona, Kentucky, Oregon, and Canada. The Hemp grown in Canada is utilized exclusively in the Canadian market and not in products sold in the United States. In furtherance of the Company’s R&D efforts, the Company established CW Labs, an internal division for R&D, to substantially expand the Company’s efforts around the science of hemp derived compounds. CW Labs is currently engaged in clinical trials addressing Hemp-based health solutions. CW Labs is located in Louisville, Colorado at the Company’s current good manufacturing practice ("cGMP") production and distribution facility.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2023 and its results of operations for the three months ended March 31, 2023 and 2022, cash flows for the three months ended March 31, 2023 and 2022, and stockholders’ equity for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2023. Inventories Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Because of the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset. Revenue Recognition The majority of the Company’s revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, and distributors, retail and wholesale business-to-business customers. The following table sets forth the disaggregation of the Company’s revenue: Three Months Ended March 31, 2023 2022 Direct-to-consumer $ 11,268 $ 13,138 Business-to-business 5,742 6,218 Total $ 17,010 $ 19,356 Substantially all of the Company’s revenue is earned in the United States. Recently Adopted Accounting Pronouncements As of March 31, 2023, there are no new accounting pronouncements adopted or issued by the FASB that had or may have a material impact on the Company’s condensed consolidated financial statements.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	FAIR VALUE MEASUREMENT The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis at March 31, 2023 and December 31, 2022, by level within the fair value hierarchy: March 31, 2023 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Holdings purchase option $ — $ — $ 2,000 $ 2,000 Debt interest rate conversion feature — — 715 715 Total Financial Assets $ — $ — $ 2,715 $ 2,715 Financial Liabilities: Debt conversion option $ — $ 6,738 $ — $ 6,738 December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Holdings purchase option $ — $ — $ 2,300 $ 2,300 Debt interest rate conversion feature — — 1,320 1,320 Total Financial Assets $ — $ — $ 3,620 $ 3,620 Financial Liabilities: Debt conversion option $ — $ 12,995 $ — $ 12,995 There were no transfers between levels of the hierarchy during the three months ended March 31, 2023 and the year ended December 31, 2022. Convertible Debt Derivatives On November 14, 2022, the Company entered into a subscription agreement (the “Subscription Agreement”) with BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group (LSE: BATS and NYSE: BTI) (the "Lender"), providing for the issuance of $56.8 million (C$75.3 million) convertible debenture (the “debenture”). The debenture is convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company on the Toronto Stock Exchange (TSX). The debenture will accrue interest at a stated annualized rate of 5% until such time that there is federal regulation permitting the use of cannabidiol, a phytocannabinoid derived from the plant Cannabis sativa L. (“CBD”) as an ingredient in food products and dietary supplements in the United States. (The term “federal regulation" is defined as the date that federal laws in the United States permit, authorize or do not prohibit the use of CBD as an ingredient in food products and dietary supplements). Following federal regulation of CBD, the annualized rate of interest shall reduce to 1.5%. The maturity date for the debenture is November 14, 2029 (the “Maturity Date”). Debt Interest Rate Conversion Feature The debt interest rate conversion feature is classified as a financial asset and is remeasured at fair value at each reporting date, with changes recognized in consolidated statements of operations as changes in fair value of financial instruments and other for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. The debt interest rate conversion feature, if triggered, reduces the stated interest rate of the debenture to 1.5% upon federal regulation of CBD in the United States. For the three months ended March 31, 2023, a $605 loss related to the debt interest rate conversion feature was recognized as a change in fair value of financial instruments and other in the statements of operations. As of March 31, 2023 and December 31, 2022, the debt interest rate conversion feature represents a financial asset of $715 and $1,320, respectively, within SBH purchase option and other derivative assets To determine the value of the option, the Company utilizes a probability weighted income approach. This method calculates the present value of the reduced interest accrued on the debenture assuming the feature is triggered at a certain time, after accounting for the probability of federal regulation of CBD. This approach is useful when ultimate valuation is based on an unverifiable outcome, such as an event outside of the Company’s influence. The following additional assumptions are used in the model: March 31, December 31, 2023 2022 Stated interest rate 5.0% 5.0% Adjusted interest rate 1.5% 1.5% Implied debt yield 12.7% 8.6% Federal regulation probability Various 15.0% Year of event Various 2025 Debt Conversion Option Per the debenture, the Lender has the option, at any time before the Maturity Date at no additional consideration, for all or any part of the principal amount to be converted into fully paid and non-assessable common shares. The Company assessed this conversion feature and determined that the debt conversion option is an embedded derivative that requires bifurcation and is classified as a financial liability. The debt conversion option is initially measured at fair value and is revalued at each reporting period using the Black-Scholes option pricing model based on Level 2 observable inputs. The assumptions used by the Company are the quoted price of the Company’s common shares in an active market, risk-free interest rate, volatility and expected life, and assumes no dividends. Volatility is based on the actual historical market activity of the Company’s shares. The expected life is based on the remaining contractual term of the debenture and the risk-free interest rate is based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected maturity of the debenture. For the three months ended March 31, 2023, a $6,257 gain related to the debt conversion option was recognized as a change in fair value of financial instruments and other in the statements of operations. As of March 31, 2023 and December 31, 2022, the debt conversion option represents a financial liability of $6,738 and $12,995, respectively, within derivative and other long-term liabilities in the condensed consolidated balance sheets. The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates: March 31, December 31, 2023 2022 Expected volatility 87.4% 86.7% Expected term (years) 6.6 6.9 Risk-free interest rate 3.6% 4.0% Expected dividend yield —% —% Value of underlying share C$0.44 C$0.73 Exercise price C$2.00 C$2.00 Stanley Brothers USA Holdings Purchase Option In 2021, the Company entered into an option purchase agreement with Stanley Brothers USA. The SBH Purchase Option was purchased for total consideration of $8,000 and has a term of five years (extendable for an additional two years upon payment of additional consideration). The SBH Purchase Option provides the Company the option to acquire all or substantially all the shares of Stanley Brothers USA on the earlier of February 26, 2025 and federal legalization of cannabis in the United States, or such earlier time as Stanley Brothers USA and the Company agree, at a purchase price to be determined at the time of exercise of the SBH Purchase Option. Upon exercise of the SBH Purchase Option, the purchase price will be determined based on application of predetermined multiples of Stanley Brothers USA revenue and earnings before interest, taxes, depreciation, and amortization (“EBITDA”) measures. The Company is not obligated to exercise the SBH Purchase Option. As part of the SBH Purchase Option agreement, Stanley Brothers USA issued the Company a warrant exercisable to purchase 10% of the outstanding Stanley Brothers USA shares and convertible securities that are considered in-the-money, subject to certain conditions and exclusions. The warrant is exercisable at the Company's election for a nominal exercise price in the event the Company elects not to acquire all or substantially all shares of Stanley Brothers USA and expires 60 days after the expiration of the option. The Company has elected the fair value option in accordance with ASC 825-10 guidance to record its SBH Purchase Option. Under ASC 825-10, a business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. The SBH Purchase Option is classified as a financial asset and is remeasured at fair value at each reporting date, with changes to fair value recognized in the statements of operations for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows. For the three months ended March 31, 2023 and 2022, a $300 loss and $100 gain, respectively, related to the SBH Purchase Option was recognized as change in fair value of financial instruments and other in the statements of operations. As of March 31, 2023 and December 31, 2022, the SBH Purchase Option represents a financial asset of $2,000 and $2,300, respectively, in the condensed consolidated balance sheets. The Monte Carlo valuation model considers multiple revenue and Earnings Before Interest Taxes Depreciation and Amortization ("EBITDA") outcomes for Stanley Brothers USA and other probabilities in assigning a fair value. Primary assumptions utilized include financial projections of Stanley Brothers USA and the probability and timing of exercise. The following additional assumptions are used in the model of the SBH Purchase Option: March 31, December 31, 2023 2022 Expected volatility 120.0% 115.0% Expected term (years) 2.4 2.7 Risk-free interest rate 4.0% 4.3% Weighted average cost of capital 42.5% 40.0%

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories consist of the following: March 31, December 31, 2023 2022 Harvested Hemp and seeds $ 34,303 $ 34,763 Raw materials 10,957 10,960 Finished goods 11,145 13,237 56,405 58,960 Less: inventory provision (30,832) (32,007) Total $ 25,573 $ 26,953

LICENSE AND MEDIA RIGHTS

LICENSE AND MEDIA RIGHTS	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
License and Media Rights	LICENSE AND MEDIA RIGHTS MLB Promotion Rights Agreement On October 11, 2022, the Company entered into a Promotional Rights Agreement (the “MLB Promotional Rights Agreement”) with MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs (collectively, the “MLB”), pursuant to which the Company entered into an strategic partnership with MLB to promote the Company’s new NSF-Certified for Sport® product line. As consideration under the MLB promotional rights agreement, the Company has paid and is committed to pay a combination of cash over the license period, along with upfront non-cash consideration in the form of equity, as well as contingent consideration in the form of contingent payments based on revenue. As of March 31, 2023 and December 31, 2022, the carrying value of the licensed properties was $20,059 and $23,399, respectively, recorded as a license and media rights asset within the condensed consolidated balance sheets. As of March 31, 2023 and December 31, 2022, the carrying value of the media rights was $7,482 recorded as a $2,500 prepaid asset and a $4,982 license and media rights asset within the condensed consolidated balance sheets. For the three months ended March 31, 2023, the Company paid the MLB $2,000 as part of the committed cash payments, and recognized $1,824 in amortization expense related to the license and media right assets. Licensed properties are amortized straight line and media rights are amortized as incurred. Maturities of the MLB license and media rights payable as of March 31, 2023 are as follows: Year Ending December 31: 2023 (9 months remaining) $ 6,000 2024 10,000 2025 12,000 Total payments $ 28,000 Less: Imputed interest (1,569) Total license and media rights payable $ 26,431 Less: Current license liabilities (10,510) Total non-current license and media rights payable $ 15,921 As of March 31, 2023, expected amortization of licensed properties are as follows: Year Ending December 31: 2023 (9 months remaining) $ 5,471 2024 7,294 2025 7,294 Total future amortization $ 20,059

DEBT

DEBT	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Convertible Debenture Effective as of November 14, 2022, the Company entered into the Subscription Agreement with BT DE Investments, Inc., providing for the issuance of $56.8 million (C$75.3 million) convertible debenture. The debenture was denominated in Canadian Dollars ("CAD" or "C$"). The debenture is convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company. The debenture will accrue interest at a stated annualized rate of 5% until such time that there is federal regulation permitting the use of CBD as an ingredient in food products and dietary supplements in the United States. Following federal regulation of CBD, the stated annualized rate of interest shall reduce to 1.5%. The maturity date for the debenture is November 14, 2029. The following is a summary of the Company's convertible debenture as of March 31, 2023 : As of March 31, 2023 Principal Amount Unamortized Debt Discount and Costs Net Carrying Amount Convertible Debenture Convertible debenture due November 2029 $ 56,760 $ (18,334) $ 38,426 The following is a summary of the Company's convertible debenture as of December 31, 2022: As of December 31, 2022 Principal Amount Unamortized Debt Discount and Costs Net Carrying Amount Convertible Debenture Convertible debenture due November 2029 $ 56,080 $ (18,659) $ 37,421 The debenture was C$75.3 million per the subscription agreement and translated to USD on the transaction date. For the three months ended March 31, 2023 , the Company recognized a foreign currency gain of $12 related to the net carrying value of the debenture within the statement of operations . Interest is accrued annually and payable on the maturity date or date of earlier conversion. On conversion, accrued interest will either be converted into common shares equal to the amount of accrued interest or will be paid in cash if agreed with the Lender. As of March 31, 2023 , the principal amount of the debenture includes $1,075 of accrued interest expense. The following is a summary of the interest expense and amortization expense, recorded within the statement of operation, of the Company's convertible debenture for the three months ended March 31, 2023: Three Months Ended March 31, Interest and Amortization Expense 2023 Interest expense $ 697 Amortization of debt discounts and costs 319 Total $ 1,016

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal ContingenciesFrom time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of March 31, 2023 there are no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
LEASES	LEASESThe Company has lease arrangements related to office space, warehouse and production space, and land to facilitate agricultural operations. The leases have remaining lease terms of less than one Maturities of operating lease liabilities as of March 31, 2023 are as follows: Operating Leases Year Ending December 31: 2023 (9 months remaining) $ 2,531 2024 3,201 2025 2,892 2026 2,169 2027 1,844 Thereafter 13,647 Total lease obligation 26,284 Less: Imputed interest (6,652) Total lease liabilities 19,632 Less: Current lease liabilities 2,268 Total non-current lease liabilities $ 17,364

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SHAREHOLDERS’ EQUITY	SHAREHOLDERS’ EQUITY As of March 31, 2023 and December 31, 2022, the Company’s share capital consists of one class of issued and outstanding shares: common shares. The Company is also authorized to issue preferred shares issuable in series. To date, no shares of preferred shares have been issued or are outstanding. Common Shares As of March 31, 2023 and December 31, 2022, the Company was authorized to issue an unlimited number of common shares, which have no par value. Share Offering Warrants – Liability Classified

LOSS PER SHARE

LOSS PER SHARE	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE The Company computes loss per share of common shares. Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding. Diluted loss per common share is computed by dividing the net loss by the weighted-average number of common shares together with the number of additional common shares that would have been outstanding if all potentially dilutive common shares had been issued, unless anti-dilutive. The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders: Three Months Ended March 31, 2023 2022 Net loss $ (2,912) $ (8,626) Weighted-average number of common shares - basic 152,314,150 144,990,224 Dilutive effect of stock options and awards — — Weighted-average number of common shares - diluted 152,314,150 144,990,224 Loss per common share – basic and diluted $ (0.02) $ (0.06) As of March 31, 2023 and March 31, 2022, potentially dilutive securities include stock options, restricted share units, common share warrants, and convertible debenture conversion. When the Company recognizes a net loss from continuing operations, all potentially dilutive shares are anti-dilutive and are consequently excluded from the calculation of diluted net loss per share. The potentially dilutive awards outstanding for each year are presented in the table below: March 31, 2023 2022 Outstanding options 4,386,215 4,867,464 Outstanding restricted share units 2,216,022 2,569,689 Outstanding common share warrants — 6,983,140 Convertible debenture conversion 37,870,349 — Total 44,472,586 14,420,293

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION Stock options Stock options vest over a prescribed service period and are approved by the board of directors on an award-by-award basis. Options have a prescribed service period generally lasting up to four years, with certain options vesting immediately upon issuance. Upon the exercise of any stock options, the Company issues shares to the award holder from the pool of authorized but unissued common shares. The fair values of options granted during the period were determined using a Black-Scholes model. The following principal inputs were used in the valuation of awards issued for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 Expected volatility 89.5% 83.4% Expected term (years) 5.5-6.5 5.5-6.5 Risk-free interest rate 3.4% 1.9% Expected dividend yield 0% 0% Value of underlying share $0.56 $1.11 Detail of the number of stock options outstanding for the three months ended March 31, 2023 under the Company's 2015 legacy option plan and the Company's amended 2018 long term incentive plan (collectively, the "Plans") is as follows: Number of Options Weighted- per Option Weighted- (in years) Aggregate Outstanding as of December 31, 2022 3,957,027 $ 1.52 8.37 $ 47 Granted 912,054 0.56 Exercised — — Forfeited (and expired) (482,866) 3.08 Outstanding as of March 31, 2023 4,386,215 $ 1.15 8.59 $ — Exercisable/vested as of March 31, 2023 1,950,323 $ 1.44 6.87 $ — The weighted average grant-date fair value of options granted during the three months ended March 31, 2023 was $0.56. The weighted average grant-date fair value of options granted during the three months ended March 31, 2022 was $1.56. The weighted average share price at the date of exercise of options exercised during the three months ended March 31, 2023 and 2022 was $0, respectively. Restricted share units The Company has issued time-based restricted share units to certain employees as permitted under the 2018 Plan. The restricted share units granted vest in accordance with the board-approved agreement, typically over equal installments over up to four years. Upon vesting, one share of the Company’s common shares is issued for each restricted share unit awarded. The fair value of each restricted share unit granted is equal to the market price of the Company’s shares at the date of the grant. The fair value of shares vested during the three months ended March 31, 2023 and March 31, 2022 was $740 and $295, respectively. Details of the number of restricted share units outstanding under the 2018 Plan is as follows: Number of Shares Weighted- Outstanding as of December 31, 2022 2,569,574 $ 0.98 Granted 304,017 $ 0.56 Forfeited (230,304) $ 3.03 Vested (297,888) $ 2.48 Shares withheld upon vesting (129,377) $ 2.51 Outstanding as of March 31, 2023 2,216,022 $ 0.78 Share-based Compensation Expense Share-based compensation expense for all equity arrangements for the three months ended March 31, 2023 and March 31, 2022 was $375 and $1,214, respectively, included in selling, general and administrative expense in the condensed consolidated statements of operations. As of March 31, 2023, $3,739 of total unrecognized share-based compensation expense related to unvested options granted to employees is expected to be recognized over a weighted-average period of 2.76 years.

INCOME AND OTHER TAXES

INCOME AND OTHER TAXES	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
INCOME AND OTHER TAXES	INCOME AND OTHER TAXES The Company’s effective tax rate in the three months ended March 31, 2023 and 2022 was 0%. The Company’s effective tax rates differ from the U.S. federal statutory rate of 21.0% for the three months end March 31, 2023 and 2022 , respectively, primarily due to the valuation allowance. The effective tax rate for the three months ended March 31, 2023 is consistent with the three months ended March 31, 2022, as the Company has been in a full valuation allowance for both periods. As of December 31, 2022, the Company qualified for federal government assistance through employee retention credit (“ERC”) provisions of the Consolidated Appropriations Act of 2021. Management recorded the ERC benefit of $4,106 for the year ended December 31, 2022 as an offset to Selling, general and administrative expense. As of March 31, 2023, the ERC is a current asset in the condensed consolidated balance sheet of $4,261, which includes $156 of interest income. The receipt of the ERC proceeds is expected during Q2 2023.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Effective November 2020, the Company entered into a secured promissory note, where $1,000 was loaned to one of the founders. The note receivable was secured by equity instruments with certain founders of the Company, and bore interest at 3.25% per annum, and required the unpaid principal and unpaid interest balances to be paid on or before the maturity date of November 13, 2023. As of March 31, 2022, the note receivable of $1,037 consisted of principal and interest. As of December 31, 2022 , the Company established a reserve against the note receivable due to decline in collateral and risk associated with collectability and therefore, expensed the outstanding balance of $1,037. Effective January 5, 2023, the Company entered into a Brand License and Option Agreement with JMS Brands LLC (the “Brand License and Option Agreement”), an entity owned by one of the Company’s founders. Pursuant to the Brand License and Option Agreement, the Company licenses certain intellectual property from JMS Brands LLC, for an annual license fee of $500. Pursuant to the terms of the agreement, the Company has the option to purchase the intellectual property rights for $2,000. On March 2, 2021, the Company entered into the SBH Purchase Option with Stanley Brothers USA as discussed above (Note 3). The SBH Purchase Option was purchased for a total consideration of $8,000. Certain founders of the Company, who are or were employees at the time, are the majority shareholders of Stanley Brothers USA.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On April 6, 2023, the Company announced the formation of an entity with AJNA BioSciences PBC (“AJNA”), and a subsidiary of British American Tobacco PLC (LSE: BATS and NYSE: BTI) (“BAT”). BAT holds an equity interest in the entity in the form of 200,000 preferred units following its $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity’s voting common units. The Company’s contribution to the entity is a license permitting the use of certain proprietary hemp intellectual property, including clinical and consumer data. AJNA's contribution to the entity is laboratory and regulatory services, clinical expertise and the provision of clinical services. The entity is expected to use the initial $10 million cash investment for the clinical development of a novel hemp botanical Investigational New Drug application and to commence Phase I clinical development in 2023.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2023 and its results of operations for the three months ended March 31, 2023 and 2022, cash flows for the three months ended March 31, 2023 and 2022, and stockholders’ equity for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2023.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Because of the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.
Revenue Recognition	Revenue Recognition The majority of the Company’s revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, and distributors, retail and wholesale business-to-business customers. The following table sets forth the disaggregation of the Company’s revenue: Three Months Ended March 31, 2023 2022 Direct-to-consumer $ 11,268 $ 13,138 Business-to-business 5,742 6,218 Total $ 17,010 $ 19,356 Substantially all of the Company’s revenue is earned in the United States.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements As of March 31, 2023, there are no new accounting pronouncements adopted or issued by the FASB that had or may have a material impact on the Company’s condensed consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Disaggregation of revenue	The following table sets forth the disaggregation of the Company’s revenue: Three Months Ended March 31, 2023 2022 Direct-to-consumer $ 11,268 $ 13,138 Business-to-business 5,742 6,218 Total $ 17,010 $ 19,356

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Financial instruments measured at fair value on a recurring basis	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis at March 31, 2023 and December 31, 2022, by level within the fair value hierarchy: March 31, 2023 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Holdings purchase option $ — $ — $ 2,000 $ 2,000 Debt interest rate conversion feature — — 715 715 Total Financial Assets $ — $ — $ 2,715 $ 2,715 Financial Liabilities: Debt conversion option $ — $ 6,738 $ — $ 6,738 December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Holdings purchase option $ — $ — $ 2,300 $ 2,300 Debt interest rate conversion feature — — 1,320 1,320 Total Financial Assets $ — $ — $ 3,620 $ 3,620 Financial Liabilities: Debt conversion option $ — $ 12,995 $ — $ 12,995
Measurement inputs	The following additional assumptions are used in the model: March 31, December 31, 2023 2022 Stated interest rate 5.0% 5.0% Adjusted interest rate 1.5% 1.5% Implied debt yield 12.7% 8.6% Federal regulation probability Various 15.0% Year of event Various 2025 March 31, December 31, 2023 2022 Expected volatility 87.4% 86.7% Expected term (years) 6.6 6.9 Risk-free interest rate 3.6% 4.0% Expected dividend yield —% —% Value of underlying share C$0.44 C$0.73 Exercise price C$2.00 C$2.00 March 31, December 31, 2023 2022 Expected volatility 120.0% 115.0% Expected term (years) 2.4 2.7 Risk-free interest rate 4.0% 4.3% Weighted average cost of capital 42.5% 40.0%

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: March 31, December 31, 2023 2022 Harvested Hemp and seeds $ 34,303 $ 34,763 Raw materials 10,957 10,960 Finished goods 11,145 13,237 56,405 58,960 Less: inventory provision (30,832) (32,007) Total $ 25,573 $ 26,953

LICENSE AND MEDIA RIGHTS (Table

LICENSE AND MEDIA RIGHTS (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of License Liability Maturity	Maturities of the MLB license and media rights payable as of March 31, 2023 are as follows: Year Ending December 31: 2023 (9 months remaining) $ 6,000 2024 10,000 2025 12,000 Total payments $ 28,000 Less: Imputed interest (1,569) Total license and media rights payable $ 26,431 Less: Current license liabilities (10,510) Total non-current license and media rights payable $ 15,921
Expected amortization of intangible assets	As of March 31, 2023, expected amortization of licensed properties are as follows: Year Ending December 31: 2023 (9 months remaining) $ 5,471 2024 7,294 2025 7,294 Total future amortization $ 20,059

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Convertible Debenture	The following is a summary of the Company's convertible debenture as of March 31, 2023 : As of March 31, 2023 Principal Amount Unamortized Debt Discount and Costs Net Carrying Amount Convertible Debenture Convertible debenture due November 2029 $ 56,760 $ (18,334) $ 38,426 The following is a summary of the Company's convertible debenture as of December 31, 2022: As of December 31, 2022 Principal Amount Unamortized Debt Discount and Costs Net Carrying Amount Convertible Debenture Convertible debenture due November 2029 $ 56,080 $ (18,659) $ 37,421
Summary of Interest Expense	The following is a summary of the interest expense and amortization expense, recorded within the statement of operation, of the Company's convertible debenture for the three months ended March 31, 2023: Three Months Ended March 31, Interest and Amortization Expense 2023 Interest expense $ 697 Amortization of debt discounts and costs 319 Total $ 1,016

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Maturities of operating lease liabilities	Maturities of operating lease liabilities as of March 31, 2023 are as follows: Operating Leases Year Ending December 31: 2023 (9 months remaining) $ 2,531 2024 3,201 2025 2,892 2026 2,169 2027 1,844 Thereafter 13,647 Total lease obligation 26,284 Less: Imputed interest (6,652) Total lease liabilities 19,632 Less: Current lease liabilities 2,268 Total non-current lease liabilities $ 17,364

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Computation of basic and diluted net loss per share	The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders: Three Months Ended March 31, 2023 2022 Net loss $ (2,912) $ (8,626) Weighted-average number of common shares - basic 152,314,150 144,990,224 Dilutive effect of stock options and awards — — Weighted-average number of common shares - diluted 152,314,150 144,990,224 Loss per common share – basic and diluted $ (0.02) $ (0.06)
Potentially dilutive awards	The potentially dilutive awards outstanding for each year are presented in the table below: March 31, 2023 2022 Outstanding options 4,386,215 4,867,464 Outstanding restricted share units 2,216,022 2,569,689 Outstanding common share warrants — 6,983,140 Convertible debenture conversion 37,870,349 — Total 44,472,586 14,420,293

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Inputs used in valuation of awards	The following principal inputs were used in the valuation of awards issued for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 Expected volatility 89.5% 83.4% Expected term (years) 5.5-6.5 5.5-6.5 Risk-free interest rate 3.4% 1.9% Expected dividend yield 0% 0% Value of underlying share $0.56 $1.11
Detail of the number of stock options outstanding	Detail of the number of stock options outstanding for the three months ended March 31, 2023 under the Company's 2015 legacy option plan and the Company's amended 2018 long term incentive plan (collectively, the "Plans") is as follows: Number of Options Weighted- per Option Weighted- (in years) Aggregate Outstanding as of December 31, 2022 3,957,027 $ 1.52 8.37 $ 47 Granted 912,054 0.56 Exercised — — Forfeited (and expired) (482,866) 3.08 Outstanding as of March 31, 2023 4,386,215 $ 1.15 8.59 $ — Exercisable/vested as of March 31, 2023 1,950,323 $ 1.44 6.87 $ —
Details of the number of restricted share awards outstanding	Details of the number of restricted share units outstanding under the 2018 Plan is as follows: Number of Shares Weighted- Outstanding as of December 31, 2022 2,569,574 $ 0.98 Granted 304,017 $ 0.56 Forfeited (230,304) $ 3.03 Vested (297,888) $ 2.48 Shares withheld upon vesting (129,377) $ 2.51 Outstanding as of March 31, 2023 2,216,022 $ 0.78

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 17,010	$ 19,356
Direct-to-consumer
Disaggregation of Revenue [Line Items]
Revenue	11,268	13,138
Business-to-business
Disaggregation of Revenue [Line Items]
Revenue	$ 5,742	$ 6,218

FAIR VALUE MEASUREMENT - Financ

FAIR VALUE MEASUREMENT - Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financial assets:
SBH purchase option and other derivative assets	$ 2,000	$ 2,300
Debt interest rate conversion feature	715	1,320
Total Financial Assets	2,715	3,620
Financial Liabilities:
Debt conversion option	6,738	12,995
Level 1
Financial assets:
SBH purchase option and other derivative assets	0	0
Debt interest rate conversion feature	0	0
Total Financial Assets	0	0
Financial Liabilities:
Debt conversion option	0	0
Level 2
Financial assets:
SBH purchase option and other derivative assets	0	0
Debt interest rate conversion feature	0	0
Total Financial Assets	0	0
Financial Liabilities:
Debt conversion option	6,738	12,995
Level 3
Financial assets:
Debt interest rate conversion feature	715	1,320
Total Financial Assets	2,715	3,620
Financial Liabilities:
Debt conversion option	$ 0	$ 0

FAIR VALUE MEASUREMENT - Narrat

FAIR VALUE MEASUREMENT - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended
	Mar. 02, 2021 USD ($)	Jan. 31, 2021 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Nov. 14, 2022 $ / shares	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt interest rate conversion feature			$ 715		$ 1,320
Derivative Asset, Statement of Financial Position [Extensible Enumeration]			SBH purchase option and other derivative assets		SBH purchase option and other derivative assets
Purchase option	$ 8,000	$ 8,000
Purchase option, term		5 years
Purchase option, extension term		2 years
Warrant, percentage of outstanding shares		10%
Warrants expiration period							60 days
Gain on change in fair value of purchase option			$ (300)	$ 100
Derivative and other long-term liabilities			6,738		$ 13,001
BAT Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, convertible, ownership percentage of shares						19.90%
Debt instrument, convertible, conversion price | $ / shares						$ 2
BAT Group | Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, annual increase, accrued interest						5%
Debt Interest Rate Conversion Feature
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain related to debt conversion			(605)
Debt Conversion Option
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain related to debt conversion			6,257
Derivative and other long-term liabilities			6,738		12,995
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt interest rate conversion feature			0		0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt interest rate conversion feature			$ 715		$ 1,320

FAIR VALUE MEASUREMENT - Fair V

FAIR VALUE MEASUREMENT - Fair Value Measure Inputs Debt Interest Rate Conversion Option (Details) - Level 3	Mar. 31, 2023	Dec. 31, 2022
Stated interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.050	0.050
Adjusted interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.015	0.015
Implied debt yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.127	0.086
Federal regulation probability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		0.150

FAIR VALUE MEASUREMENT - Schedu

FAIR VALUE MEASUREMENT - Schedule of Level 2 Fair Value Measurements (Details) - Level 2	Mar. 31, 2023 CAD ($)	Dec. 31, 2022 CAD ($)
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.874	0.867
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	6.6	6.9
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.036	0.040
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0
Value of underlying share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.44	0.73
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	2	2

FAIR VALUE MEASUREMENT - Fair_2

FAIR VALUE MEASUREMENT - Fair Value Measurement Inputs - Purchase Option (Details) (Details)	Mar. 31, 2023	Dec. 31, 2022
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	1.200	1.150
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	2.4	2.7
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	0.040	0.043
Weighted average cost of capital
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	0.425	0.400

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Harvested Hemp and seeds	$ 34,303	$ 34,763
Raw materials	10,957	10,960
Finished goods	11,145	13,237
Inventory, gross	56,405	58,960
Less: inventory provision	(30,832)	(32,007)
Inventories, net	$ 25,573	$ 26,953

LICENSE AND MEDIA RIGHTS - Narr

LICENSE AND MEDIA RIGHTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Other Commitments [Line Items]
Licensed Properties	$ 20,059	$ 23,399
License and media rights	7,482	7,482
License and media rights	2,500	2,500
Prepaid media rights, noncurrent	4,982	4,982
License and media rights	25,041	$ 26,871
Licensing Agreements
Other Commitments [Line Items]
Amortization	1,824
Major League Baseball Properties Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Payments for license fee	$ 2,000

LICENSE AND MEDIA RIGHTS - Sche

LICENSE AND MEDIA RIGHTS - Schedule of License Liability Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Commitments [Line Items]
License and media rights payable - current	$ 10,510	$ 7,759
License and media rights payable - noncurrent	15,921	$ 20,383
Licensing Agreements
Other Commitments [Line Items]
2023 (9 months remaining)	6,000
2024	10,000
2025	12,000
Total payments	28,000
Less: Imputed interest	1,569
Total license and media rights payable	$ 26,431

LICENSE AND MEDIA RIGHTS - Amor

LICENSE AND MEDIA RIGHTS - Amortization of License (Details) - Licensing Agreements $ in Thousands	Mar. 31, 2023 USD ($)
Other Commitments [Line Items]
2023 (9 months remaining)	$ 5,471
2024	7,294
2025	7,294
Total future amortization	$ 20,059

DEBT (Details)

DEBT (Details) - BAT Group $ / shares in Units, $ in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Nov. 14, 2022 USD ($)	Nov. 14, 2022 CAD ($) $ / shares
Line of Credit Facility [Line Items]
Debt instrument, convertible, ownership percentage of shares			19.90%	19.90%
Debt instrument, convertible, conversion price | $ / shares				$ 2
Interest Payable	$ 1,075
Convertible Notes Payable
Line of Credit Facility [Line Items]
Principal amount	56,760	$ 56,080	$ 56,800	$ 75.3
Foreign currency gain	$ 12
Minimum
Line of Credit Facility [Line Items]
Debt instrument, annual increase, accrued interest			5%	5%
Maximum
Line of Credit Facility [Line Items]
Debt instrument, annual increase, accrued interest			1.50%	1.50%

Debt - Summary of Convertible D

Debt - Summary of Convertible Debenture (Details) - BAT Group - Convertible Notes Payable $ in Thousands, $ in Millions	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Nov. 14, 2022 USD ($)	Nov. 14, 2022 CAD ($)
Line of Credit Facility [Line Items]
Principal amount	$ 56,760	$ 56,080	$ 56,800	$ 75.3
Unamortized Debt Discount and Costs	(18,334)	(18,659)
Net Carrying Amount	$ 38,426	$ 37,421

DEBT - Summary of Interest Expe

DEBT - Summary of Interest Expense (Details) - BAT Group $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Line of Credit Facility [Line Items]
Interest expense	$ 697
Amortization of debt discounts and costs	319
Total	$ 1,016

LEASES - Narrative (Details)

LEASES - Narrative (Details)	Mar. 31, 2023
Lessee, Lease, Description [Line Items]
Renewal term	5 years
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	7 months 31 days
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	12 years

LEASES - Maturities of Operatin

LEASES - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Year Ending December 31:
2023 (9 months remaining)	$ 2,531
2024	3,201
2025	2,892
2026	2,169
2027	1,844
Thereafter	13,647
Total lease obligation	26,284
Less: Imputed interest	(6,652)
Total lease liabilities	19,632
Less: Current lease liabilities	2,268	$ 2,306
Total non-current lease liabilities	$ 17,364	$ 17,905

SHAREHOLDERS_ EQUITY - Narrativ

SHAREHOLDERS’ EQUITY - Narrative (Details) - $ / shares	Mar. 31, 2023	Mar. 31, 2022
Equity [Abstract]
Warrants outstanding (in shares)	0	6,983,140
Weighted average warrants outstanding (in USD per share)		$ 7.86

LOSS PER SHARE - Basic and Dilu

LOSS PER SHARE - Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss	$ (2,912)	$ (8,626)
Weighted-average number of common shares - basic (in shares)	152,314,150	144,990,224
Dilutive effect of stock options and awards (in shares)	0	0
Weighted-average number of common shares - diluted (in shares)	152,314,150	144,990,224
Loss per common share - basic (in usd per share)	$ (0.02)	$ (0.06)
Loss per common share - diluted (in usd per share)	$ (0.02)	$ (0.06)

LOSS PER SHARE - Potentially Di

LOSS PER SHARE - Potentially Dilutive Awards (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	44,472,586	14,420,293
Outstanding options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	4,386,215	4,867,464
Outstanding restricted share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	2,216,022	2,569,689
Outstanding common share warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	0	6,983,140
Convertible debenture conversion
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	37,870,349	0

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, weighted average grant-date fair value (in usd per share)	$ 0.56	$ 1.56
Options exercised, weighted average share price (in usd per share)	$ 0	$ 0
Fair value of shares vested	$ 740	$ 295
Share-based compensation expense	375	$ 1,214
Unrecognized share based compensation expense	$ 3,739
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Prescribed service period	4 years
Unrecognized share based compensation expense, period for recognition	2 years 9 months 3 days	2 years 9 months 3 days
Restricted share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

SHARE-BASED COMPENSATION - Fair

SHARE-BASED COMPENSATION - Fair Value Inputs (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	89.50%	83.40%
Risk-free interest rate	3.40%	1.90%
Expected dividend yield	0%	0%
Value of underlying share (in usd per share)	$ 0.56	$ 1.11
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years 6 months	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 6 months	6 years 6 months

SHARE-BASED COMPENSATION - Opti

SHARE-BASED COMPENSATION - Options Outstanding (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Number of Options
Outstanding (in shares)	3,957,027
Granted (in shares)	912,054
Exercised (in shares)	0
Forfeited (and expired) (in shares)	(482,866)
Outstanding (in shares)	4,386,215	3,957,027
Exercisable/vested (in shares)	1,950,323
Weighted-Average Exercise Price Per Option
Outstanding (in usd per share)	$ 1.15	$ 1.52
Granted (in usd per share)	0.56
Exercised (in usd per share)	0
Forfeited (and expired) (in usd per share)	3.08
Outstanding (in usd per share)	1.15	$ 1.52
Exercisable/vested (in usd per share)	$ 1.44
Weighted-Average Remaining Contract Term
Outstanding	8 years 7 months 2 days	8 years 4 months 13 days
Exercisable/vested	6 years 10 months 13 days
Aggregate Intrinsic Value
Outstanding	$ 0	$ 47,000
Exercisable/vested	$ 0

SHARE-BASED COMPENSATION - Rest

SHARE-BASED COMPENSATION - Restricted Share Units Outstanding (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of Shares
Outstanding (in shares) | shares	2,569,574
Granted (in shares) | shares	304,017
Forfeited (in shares) | shares	(230,304)
Vested (in shares) | shares	(297,888)
Shares withheld upon vesting (in shares) | shares	(129,377)
Outstanding (in shares) | shares	2,216,022
Weighted-Average Grant Date Fair Value
Outstanding (in usd per share) | $ / shares	$ 0.98
Granted (in usd per share) | $ / shares	0.56
Forfeited (in usd per share) | $ / shares	3.03
Vested (in usd per share) | $ / shares	2.48
Shares withheld upon vesting (in usd per share) | $ / shares	2.51
Outstanding (in usd per share) | $ / shares	$ 0.78

INCOME TAXES AND OTHER TAXES (D

INCOME TAXES AND OTHER TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	0%	0%
Federal income tax rate	21%	21%
ERC benefit			$ 4,106
Income tax refunds received	$ 4,261
Interest income on ERC	$ 156

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands					1 Months Ended	3 Months Ended
	Jan. 05, 2023	Apr. 16, 2021	Mar. 02, 2021	Nov. 30, 2020	Jan. 31, 2021	Mar. 31, 2022	Mar. 31, 2023
Related Party Transaction [Line Items]
Note receivable from related party				$ 1,000		$ 1,037	$ 1,037
Note receivable interest rate				3.25%
Purchase option			$ 8,000		$ 8,000
Related party consulting services
Related Party Transaction [Line Items]
Related party expenses						$ 420
Consulting agreement, extended term		1 year
Payments to related party		$ 2,081
Related Party Licensing Agreement
Related Party Transaction [Line Items]
Purchase option of intellectual property rights	$ 2,000
Related Party Licensing Agreement | JMS Brands
Related Party Transaction [Line Items]
Related party expenses	$ 500

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event - Joint Venture With AJNA And BAT $ in Millions	Apr. 06, 2023 USD ($) shares
Subsequent Event [Line Items]
Preferred units outstanding (in shares)	400,000
British American Tobacco
Subsequent Event [Line Items]
Preferred units outstanding (in shares)	200,000
Preferred units investment | $	$ 10
AJNA Biosciences
Subsequent Event [Line Items]
Preferred units outstanding (in shares)	400,000